Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Dr. Huiqiang Huang: Combining PD-1 Monoclonal Antibody and HDAC Inhibitor with Conventional P-Gemox Significantly Improves the Treatment Outcome for NK/T Cell Lymphoma

    Editor’s Note: From June 17th to 23rd, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held grandly in Lugano, Switzerland. As the world’s largest conference on malignant lymphoma,…

    2024.01.11
  • Strategy First! UCLI-ICML Joint Session Lays Foundation for Collaboration

    Editor’s note: From June 13-17, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held in Lugano, Switzerland. As the largest international conference on malignant lymphoma, the event gathered…

    2024.01.11
  • The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

    “The Hepatology Digest -Liver Vascular Disease Column” is an academic section jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater General Hospital, at the invitation of the Hepatology Digest editorial team. It regularly collects and discusses the latest research in the field of liver vascular diseases. Every two weeks, on Wednesdays,…

    2024.01.11
  • The Treatment and Clinical Cure of Childhood Hepatitis B

    China is a country with a high incidence of hepatitis B, and mother-to-child transmission is an important route for children in China to contract the hepatitis B virus (HBV). Although chronic HBV infection in childhood rarely progresses to active hepatitis, there is still a risk of developing cirrhosis and liver cancer. Therefore, understanding the epidemiological…

    2024.01.10
  • Strategies to Optimize CAR-T Cell Therapy in Hematological Malignancies: Chinese Experience

    🩸 Advancements in Hematological Malignancies: Professor Xiaojun Huang’s Insights on CAR-T Cell Therapy In the landscape of oncology, hematological malignancies cast a formidable shadow, spanning leukemia, lymphoma, and multiple myeloma. Yet, amidst these intricate conditions, a beacon of hope emerges through the transformative strides of CAR-T cell therapy. This groundbreaking approach stands as a promising…

    2024.01.10
  • Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic

    🩸 Resilience Amidst Crisis: Prof. Xiaojun Huang’s Pioneering Insights on HSCT during COVID-19 In a world disrupted by the SARS-CoV-2 pandemic, the adaptability and innovation of medical practices became imperative. An illuminating study, recently unveiled in Transplantation and Cellular Therapy’s February 2023 publication, sheds light on a beacon of hope amidst this chaos. Titled “Hematopoietic…

    2024.01.10
  • Professor Xiaojun Huang ‘s Team Reveals New Mechanism of Injury to Bone Marrow Endothelial Progenitor Cells and Proposes Targeted Repair Strategies

    🩸 Professor Xiaojun Huang and Team: Illuminating Hope in Blood Health Meet the unsung heroes—Professor Xiaojun Huang and their dedicated team—who’ve ventured into the labyrinth of blood health, uncovering a profound truth within our marrow’s tapestry. They’ve unraveled a poignant narrative—a disruption in glycolysis, a hidden force causing turmoil for endothelial progenitor cells (EPCs). This…

    2024.01.10
  • CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

    Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these conditions is beneficial for reducing the burden of disease. To support the development of diabetes and liver disease co-management in China, this publication Hepatology Digest,…

    2024.01.10
«previous next»
Recent Posts
  • CACA GU丨Yiping Zhu: Advancing Standardized, Whole-Course Bladder Cancer Management—from First-Line Treatment Innovation to Multidisciplinary Collaboration
  • 2026 Pujiang Urological Oncology Academic Conference丨Yijun Shen: ADCs Are Driving Bladder-Preservation Strategies Toward Precision Combination Therapy—from Combination Treatment in High-Risk NMIBC and MIBC Pathway Reshaping to Molecular Biomarker Stratification
  • 2026 Pujiang Urological Oncology Academic Conference丨Professor Guohai Shi: From Combination Therapy to Whole-Course Management, Advancing Long-Term Benefit in Advanced Renal Cell Carcinoma
  • CACA GU丨Professor Xin Yao: Advancing Full-Course Urological Cancer Management Through Precision, Refinement, and Continuous Excellence
  • Joe M. O’Sullivan Professor: APCCC 2026 Updates and Insights — Controversies in Hormonal Therapy Sequencing and Combination Strategies, the Prospects of Radioligand Therapy, and Global Equity in Prostate Cancer Care
Recent Comments
    Archives
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top